|University of Illinois at Chicago, PhD||1990|
|University of Illinois at Urbana-Champaign, BS||1984|
Jay Lichter, PhD is an experienced biotechnology and pharmaceutical business executive with 25 years of experience in management, scientific research, and business development.
He led Avalon VIII’s investments in and served as Director and CEO for Afraxis, Carolus, Otonomy, ReVision Therapeutics and Zacharon.
He also led the first life science investment for Avalon IX, Sova Pharmaceuticals and serves as the CEO and on the Board of Directors.
Throughout his career, Dr. Lichter has applied his exceptional combination of business acumen and deep technical knowledge to creating commercially successful biotech collaborations and identifying the commercial potential of scientific discoveries at their earliest stages.
Dr. Lichter is the inventor on 260 patent and patent applications for six Avalon portfolio companies, including 55 issued patents.
Dr. Lichter has been either directly responsible for or participated in licensing or merger and acquisition deals valued in excess of $1 billion.